The BYL-719 study showed that the combination of alpelisib and T-DM1 had better safety and efficacy in patients with trastuzumab-resistant HER-2-positive advanced breast cancer, and the objective response rate (ORR) was higher than that of T-DM1 alone. The gene discussed is ERBB2; the disease is breast carcinoma.